Simcere Pharmaceutical Group (FRA:S2P) NonCurrent Deferred Liabilities: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S2P Simcere Pharmaceutical Group Ltd FRA:S2P
86 GF Score
Price €1.36
GF Value €1.15
Valuation Modestly Overvalued
View Full Analysis

What is Simcere Pharmaceutical Group NonCurrent Deferred Liabilities?

Simcere Pharmaceutical Group FRA:S2P -2.86% 86 NonCurrent Deferred Liabilities is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:S2P with a GF Score™ of 86/100 and a GF Value™ of €1.15 (Modestly Overvalued).

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Simcere Pharmaceutical Group's non-current deferred liabilities for the quarter that ended in Dec. 2025 was €0.0 Mil.

Simcere Pharmaceutical Group NonCurrent Deferred Liabilities Related Terms

Simcere Pharmaceutical Group NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group NonCurrent Deferred Liabilities Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:S2P
86GF Score
Simcere Pharmaceutical Group Ltd FRA:S2P
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.0 Mil mean?
Simcere Pharmaceutical Group (FRA:S2P) has a NonCurrent Deferred Liabilities of €0.0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's NonCurrent Deferred Liabilities too high?
Simcere Pharmaceutical Group's current NonCurrent Deferred Liabilities is €0.0 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's NonCurrent Deferred Liabilities compare to ZTS and UTHR?
Simcere Pharmaceutical Group's NonCurrent Deferred Liabilities of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current NonCurrent Deferred Liabilities is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.15, compared to a current price of €1.36 — trading 18.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0.0 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current NonCurrent Deferred Liabilities is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.36 is trading 18.3% above its estimated GF Value™ of €1.15. GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for FRA:S2P:

  • NonCurrent Deferred Liabilities: €0.0 Mil
  • GF Value™: €1.15 vs. price of €1.36 (18.3% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
86GF Score

Get the complete analysis for FRA:S2P

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price
€1.15
GF Value